On February 17, 2026, ENAVATE Sciences GP, LLC announced a purchase of 157,800 shares of Zenas BioPharma (ZBIO), valued at approximately $5.19 million. This transaction increased ENAVATE’s total holding in Zenas to 3,919,159 shares, making it the fund’s largest position at 28.1% of its $506.78 million in reportable assets under management (AUM). The value of Zenas’s stake rose by about $58.80 million during the quarter due to both the purchase and significant stock price appreciation.
This move highlights ENAVATE’s concentrated investment strategy in high-conviction biotech plays, particularly in Zenas, which has seen its shares surge 167% over the past year, vastly outperforming the S&P 500. The company is focused on developing innovative therapies for autoimmune diseases, with key milestones approaching, including a planned BLA submission for its lead candidate, obexelimab, in Q2 2026.
For market professionals, the key takeaway is that while ENAVATE’s recent buy reflects confidence in Zenas’s pipeline, the upcoming regulatory submissions and clinical data releases will be crucial in determining the stock’s trajectory. Monitoring these developments will be essential for assessing investment risks and opportunities in this high-stakes sector.
Source: fool.com